Deep Discounts Continue

Prices slashed for first biotech IPOs of 2011: Pacira, Endocyte, BG Medicine

Deep discounts continue

The final U.S. IPOs in 2010 slashed their deal prices more than in half just before pricing. If the first few IPOs this year are any indication, that pattern will continue.

The first IPO out this year - specialty pain play Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) - cut its price to

Read the full 511 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE